NYSE:BMYPharmaceuticals
Bristol Myers Squibb Leans On AI ALS Pact As Valuation Question Persists
Bristol-Myers Squibb (NYSE:BMY) has expanded its partnership with insitro to pursue disease-modifying therapies for amyotrophic lateral sclerosis (ALS).
The collaboration adds new ALS targets sourced from insitro’s AI driven Virtual Human platform and multimodal discovery approach.
The partners aim to accelerate discovery and development of multiple ALS candidates in an area with significant unmet medical need.
Bristol-Myers Squibb, trading at about $57.39, is extending this AI focused...